ArticleCancers2026
Optimizing Systematic Endoscopic Lymph Node Staging in Non-Small Cell Lung Cancer: Proposals for Integrating the 9th Edition N-Staging Classification into Clinical Practice.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Systematic endoscopic mediastinal lymph node staging is imperative to most accurately define the extent of LN involvement in patients with locally advanced (cN2) NSCLC. It provides the most accurate nodal information in comparison to imaging techniques and is the most likely investigation to differentiate N2a from N2b disease. Accumulation of evidence to validate the prognostic, and potentially the predictive value of accurately defining N2a and N2b N-status will be supported by more consistent and more comprehensive mediastinal endoscopic staging in this group, aided by more detailed (synoptic) reporting. We identify proposed solutions for enhancement of systematic staging in patients with N2 NSCLC, including routine performance of systematic lymph node assessment, with sampling of all LN > 6 mm, addition of EUS-B-FNA where possible, and use of synoptic reporting to reduce variance in care and enable performance monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.